In 2020, SONIRE was found and began developing a novel ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system. HIFU therapy is a treatment method that focuses ultrasound waves emitted from outside the body to the target site and thermally coagulates tissue at the target site and has the following three features, non-invasive, radiation-free and short-time treatment. Currently, SONIRE is conducting a randomized controlled trial “SUNRISE-I Study” for unresectable pancreatic cancer as the first indication in Japan, using the investigational device “Suizenji” developed by the company itself, and planning to start clinical studies targeting unresectable pancreatic cancer in the U.S. and metastatic liver cancer in Japan.